What is AC Immune S.A. (ACIU)?

AC Immune S.A. (ACIU) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of ACIU?

The current price of ACIU is $2.37. Prices are updated in real time on Stocks360.

What is ACIU's price-to-earnings (PE) ratio?

ACIU's trailing twelve-month PE ratio is -4.55, based on current price and earnings per share data available on Stocks360.

What is ACIU's market capitalization?

ACIU's market capitalization is $241,203,347.00, placing it in the small-cap tier.

AC Immune S.A. (ACIU)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$2.37

Market Cap

$241.20M

PE (TTM)

-4.55

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.55

Day Range

$2.20 – $2.38

52-wk Range

$2.03 – $4.00

Avg Volume

N/A

Volume

227.12K

AC Immune S.A. (ACIU) is a publicly traded company in the Healthcare sector. Latest price: $2.37. Market cap $241.20M. Trailing PE -4.55. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-29 · $3.84 2026-10-28 · $2.37 (-38.28%)

Earnings

Most Recent

Aug 5, 2026

EPS $0.03 vs est. $-0.10

Beat by $0.13

Next Earnings

Nov 3, 2026

EPS estimate $-0.22

Proprietary Signals

Signal snapshot temporarily unavailable.

About AC Immune S.A.

AC Immune S.A. is a biotech firm operating at the clinical stage, dedicated to pioneering, formulating, and advancing therapeutic agents and diagnostic tools. Its core mission is addressing neurodegenerative conditions rooted in protein misfolding, both preventatively and therapeutically. Leveraging its proprietary SupraAntigen and Morphomer platforms, the company engineers a range of vaccines, antibodies, and small molecules specifically designed to engage with aberrantly folded proteins implicated across various neurodegenerative disorders. Its pipeline features Crenezumab, a humanized, conformation-specific monoclonal antibody currently undergoing a Phase II clinical prevention trial for Alzheimer's disease (AD). Additionally, AC Immune is advancing ACI-24, an anti-Abeta vaccine candidate, which is in Phase II clinical evaluation for AD and has successfully completed a Phase Ib study for Down syndrome. Other key candidates include ACI-35, an anti-Tau vaccine candidate that has finished Phase Ib clinical assessment, and a Tau-positron emission tomography (PET) imaging tracer, also in Phase II development. Furthermore, the company is engaged in the research and development of sma…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-4.55×
P/S (TTM)	11.40×
P/B	5.50×
PEG	0.22×
P/FCF (TTM)	-5.71×
EV / EBITDA	-4.22×
EV / Sales	10.05×
Earnings Yield	-22.31%
Free Cash Flow Yield	-17.52%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$175.90M
Revenue (TTM)	$17.51M
Net Income (TTM)	-$44.51M
Free Cash Flow (TTM)	-$34.79M
Net Debt	-$23.66M
Working Capital	-$6.84M
Gross Margin	100.00%
Operating Margin	-252.25%
Net Margin	-246.49%
Return on Equity	-99.17%
Return on Invested Capital	-86.61%